A Pharmacological Screening Approach for Discovery of Neuroprotective Compounds in Ischemic Stroke

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Beraki, Simret ^a   Litrus, Lily ^b   Soriano, Liza ^c   Monbureau, Marie ^a   To, Lillian K ^a   Braithwaite, Steven P ^d   Nikolich, Karoly ^d   Urfer, Roman ^e   Oksenberg, Donna ^f   Shamloo, Mehrdad ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BioSeek A Division of DiscoveRx Inc   (United States)

^c Pacific BioDevelopment Limited Liability Company   (United States)

^d Circuit Therapeutics Inc   (United States)

^e Selonterra Limited Liability Company   (United States)

^f Global Blood Therapeutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ACETAZOLAMIDE; AMIPRILOSE; ANTIOXIDANT; AZATHIOPRINE; CARBENOXOLONE; CHLOROTHIAZIDE; CLOFIBRIC ACID; CYCLOPHOSPHAMIDE; DAPSONE; FENSPIRIDE; GANCICLOVIR; GLUCOCORTICOID; GLUCOSE; GRISEOFULVIN; IDOXURIDINE; LATAMOXEF; LIOTHYRONINE; MECLOFENOXATE; METHOTREXATE; MONOAMINE OXIDASE INHIBITOR; OXYGEN; PHENACETIN; PILOCARPINE; PIPERINE; SULFAMONOMETHOXINE; SULFAPHENAZOLE; SULFINPYRAZONE; TRANEXAMIC ACID; UNINDEXED DRUG;

ARTICLE; BRAIN CELL; BRAIN ISCHEMIA; DRUG MECHANISM; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; SCREENING TEST;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANALYSIS OF VARIANCE; BRAIN ISCHEMIA; CARBENOXOLONE; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GLUCOCORTICOIDS; HIGH-THROUGHPUT SCREENING ASSAYS; HIPPOCAMPUS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PROPIDIUM; STATISTICS, NONPARAMETRIC;

EID: 84880425198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069233     Document Type: Article

References (49)

1. Towfighi A, Saver JL, (2011) Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 42: 2351-2355.
2. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP, (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40: 2945-2948.
3. Finley Caulfield A, Wijman CA (2006) Critical care of acute ischemic stroke. Crit Care Clin 22: 581-606: abstract vii.
4. Lipton P, (1999) Ischemic cell death in brain neurons. Physiol Rev 79: 1431-1568.
5. Tymianski M, (2011) Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci 14: 1369-1373.
6. Rozental R, Srinivas M, Spray DC, (2001) How to close a gap junction channel. Efficacies and potencies of uncoupling agents. Methods Mol Biol 154: 447-476.
7. Sewell KJ, Shirley DG, Michael AE, Thompson A, Norgate DP, et al. (1998) Inhibition of renal 11beta-hydroxysteroid dehydrogenase in vivo by carbenoxolone in the rat and its relationship to sodium excretion. Clin Sci (Lond) 95: 435-443.
8. Seckl JR, Kelly PA, Sharkey J, (1991) Glycyrrhetinic acid, an inhibitor of 11 beta-hydroxysteroid dehydrogenase, alters local cerebral glucose utilization in vivo. J Steroid Biochem Mol Biol 39: 777-779.
9. Stewart PM, Krozowski ZS, (1999) 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 57: 249-324.
10. White PC, Mune T, Agarwal AK, (1997) 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135-156.
11. Rajan V, Edwards CR, Seckl JR, (1996) 11 beta-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci 16: 65-70.
12. Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y,et al. Lack of tissue glucocorticoid reactivation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci U S A 98: 4716-4721.
13. Khorasani MZ, Hosseinzadeh SA, Vakili A, (2009) Effect of central microinjection of carbenoxolone in an experimental model of focal cerebral ischemia. Pak J Pharm Sci 22: 349-354.
14. Vakili A, Hosseinzadeh SA, Khorasani MZ, (2009) Peripheral administration of carbenoxolone reduces ischemic reperfusion injury in transient model of cerebral ischemia. J Stroke Cerebrovasc Dis 18: 81-85.
15. Stoppini L, Buchs PA, Muller D, (1991) A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182.
16. Cronberg T, Rytter A, Asztély F, Söder A, Weiloch T, (2004) Glucose but not lactate in combination with acidosis aggravates ischemic neuronal death in vitro. Stroke 35: 753-757.
17. Brewer GJ, (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 42: 674-683.
18. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, et al. (2005) Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem 280: 42290-42299.
19. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH, (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 88: 6368-6371.
20. Memezawa H, Minamisawa H, Smith ML, Siesjo BK, (1992) Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res 89: 67-78.
21. Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, et al. (2006) Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. Brain Res 1116: 159-165.
22. Frantseva MV, Kokarovtseva L, Naus CG, Carlen PL, MacFabe D,et al. Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury. J Neurosci 22: 644-653.
23. Frantseva MV, Kokarovtseva L, Perez Velazquez JL, (2002) Ischemia-induced brain damage depends on specific gap-junctional coupling. J Cereb Blood Flow Metab 22: 453-462.
24. Naus CC, Ozog MA, Bechberger JF, Nakase T, (2001) A neuroprotective role for gap junctions. Cell Commun Adhes 8: 325-328.
25. Zundorf G, Kahlert S, Reiser G, (2007) Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture. J Neurochem 102: 508-521.
26. de Pina-Benabou MH, Szostak V, Kyrozis A, Rempe D, Uziel D, et al. (2005) Blockade of gap junctions in vivo provides neuroprotection after perinatal global ischemia. Stroke 36: 2232-2237.
27. Sandeep TC, Walker BR, (2001) Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 12: 446-453.
28. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, et al. (2004) 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101: 6734-6739.
29. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, et al. (1987) Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2: 821-824.
30. Leshchenko Y, Likhodii S, Yue W, Burnham WM, Perez Velazquez JL, (2006) Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci 7: 3.
31. Rawanduzy A, Hansen A, Hansen TW, Nedergaard M, (1997) Effective reduction of infarct volume by gap junction blockade in a rodent model of stroke. J Neurosurg 87: 916-920.
32. Rouach N, Segal M, Koulakoff A, Giaume C, Avignone E, (2003) Carbenoxolone blockade of neuronal network activity in culture is not mediated by an action on gap junctions. J Physiol 553: 729-745.
33. Perez Velazquez JL, Frantseva MV, Carlen PL, (1997) In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons. J Neurosci 17: 9085-9094.
34. Bonvalet JP, Doignon I, Blot-Chabaud M, Pradelles P, Farman N, (1990) Distribution of 11 beta-hydroxysteroid dehydrogenase along the rabbit nephron. J Clin Invest 86: 832-837.
35. Morita H, Zhou M, Foecking MF, Gomez-Sanchez EP, Cozza EN,et al. 11 beta-Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11 alpha-hydroxyprogesterone. Endocrinology 137: 2308-2314.
36. Holmes MC, Seckl JR, (2006) The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol 248: 9-14.
37. New MI, Wilson RC, (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 96: 12790-12797.
38. Jamieson PM, Chapman KE, Edwards CR, Seckl JR, (1995) 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136: 4754-4761.
39. Jamieson PM, Fuchs E, Flugge G, Seckl JR, (1997) Attenuation of Hippocampal 11beta-Hydroxysteroid Dehydrogenase Type 1 by Chronic Psychosocial Stress in the Tree Shrew. Stress 2: 123-132.
40. Grosser BI, (1966) 11-beta-Hydroxysteroid metabolism by mouse brain and glioma 261. J Neurochem 13: 475-478.
41. Grosser BI, Axelrod LR, (1968) Conversion of cortisol to cortisol acetate, cortisone acetate and cortisone by the developing primate brain. Steroids 11: 827-836.
42. Peterson NA, Chaikoff IL, Jones C, (1965) The in Vitro Conversion of Cortisol to Cortisone by Subcellular Brain Fractions of Young and Adult Rats. J Neurochem 12: 273-278.
43. Wyrwoll CS, Holmes MC, Seckl JR, (2011) 11beta-hydroxysteroid dehydrogenases and the brain: from zero to hero, a decade of progress. Front Neuroendocrinol 32: 265-286.
44. Rosmond R, Bjorntorp P, (2000) The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med 247: 188-197.
45. Korz V, Frey JU, (2003) Stress-related modulation of hippocampal long-term potentiation in rats: Involvement of adrenal steroid receptors. J Neurosci 23: 7281-7287.
46. Zipp F, Aktas O, (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29: 518-527.
47. Sorrells SF, Sapolsky RM, (2007) An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 21: 259-272.
48. O'Collins VE, Macleod MR, Cox SF, Van Raay L, Aleksoska E, et al. (2011) Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab, 31, 962-975.
49. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, et al. (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69: 1404-1410.